ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.

Related Keywords

United States ,America ,Kennethc Anderson , ,Johnson ,Oncologic Drugs Advisory Committee ,Bristol Myers Squibb ,Meeting Of The Oncologic Drugs Advisory Committee ,Drugs Advisory Committee ,D ,Dana Farber Cancer Institute ,Hodac ,Fda ,Decabtagene Vicleucel Ide Cel Abecma ,Ciltacabtagene Autoleucel Cilta Cel Carvykti ,